Published in Genome Med on March 31, 2014
Hypermutation in human cancer genomes: footprints and mechanisms. Nat Rev Cancer (2014) 1.67
An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers. Nat Genet (2015) 1.29
EPMA position paper in cancer: current overview and future perspectives. EPMA J (2015) 1.04
Genomic approaches to DNA repair and mutagenesis. DNA Repair (Amst) (2015) 0.86
Renal cell carcinomas of chronic kidney disease patients harbor the mutational signature of carcinogenic aristolochic acid. Int J Cancer (2014) 0.86
Next generation sequencing of Cytokeratin 20-negative Merkel cell carcinoma reveals ultraviolet-signature mutations and recurrent TP53 and RB1 inactivation. Mod Pathol (2016) 0.84
Mutation signatures implicate aristolochic acid in bladder cancer development. Genome Med (2015) 0.84
High-throughput sequencing in mutation detection: A new generation of genotoxicity tests? Mutat Res (2015) 0.82
Clusters of Multiple Mutations: Incidence and Molecular Mechanisms. Annu Rev Genet (2015) 0.78
Low-Coverage Exome Sequencing Screen in Formalin-Fixed Paraffin-Embedded Tumors Reveals Evidence of Exposure to Carcinogenic Aristolochic Acid. Cancer Epidemiol Biomarkers Prev (2015) 0.77
Exploring the Mechanisms of Gastrointestinal Cancer Development Using Deep Sequencing Analysis. Cancers (Basel) (2015) 0.75
*K-means and cluster models for cancer signatures. Biomol Detect Quantif (2017) 0.75
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
Signatures of mutational processes in human cancer. Nature (2013) 21.63
A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature (2009) 18.39
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
Mutational processes molding the genomes of 21 breast cancers. Cell (2012) 11.22
Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst (2008) 8.14
Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 7.77
DNA damage, aging, and cancer. N Engl J Med (2009) 7.56
Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene (2002) 7.04
Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet (1993) 6.56
Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet (2012) 6.25
Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer (2002) 6.08
Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer (2003) 5.97
DNA repair, genome stability, and aging. Cell (2005) 5.52
APOBEC3B is an enzymatic source of mutation in breast cancer. Nature (2013) 5.18
Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet (2012) 4.82
An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet (2013) 4.69
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science (2013) 4.42
Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet (1992) 4.11
Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet (2013) 3.94
Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet (2012) 3.63
Deciphering signatures of mutational processes operative in human cancer. Cell Rep (2013) 3.61
The Ames Salmonella/microsome mutagenicity assay. Mutat Res (2000) 3.51
Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet (2011) 3.10
Temozolomide and treatment of malignant glioma. Clin Cancer Res (2000) 2.95
Aristolochic acid nephropathy: a worldwide problem. Kidney Int (2008) 2.73
Cancer epidemiology in the last century and the next decade. Nature (2001) 2.72
Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev (1997) 2.62
Identification of mismatch repair genes and their role in the development of cancer. Curr Opin Genet Dev (1995) 2.37
Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing. Sci Transl Med (2013) 2.30
The specificity of UV-induced mutations at an endogenous locus in mammalian cells. Proc Natl Acad Sci U S A (1987) 2.26
Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet (2013) 2.15
MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res (2009) 2.11
Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. Sci Transl Med (2013) 2.07
Lung carcinogenesis by tobacco smoke. Int J Cancer (2012) 2.06
The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death. Cancer Res (2005) 1.93
Smoking-related DNA and protein adducts in human tissues. Carcinogenesis (2002) 1.91
Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis (2002) 1.90
The mechanisms of UV mutagenesis. J Radiat Res (2011) 1.88
Aristolochic acid-associated urothelial cancer in Taiwan. Proc Natl Acad Sci U S A (2012) 1.82
p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet (1991) 1.81
Mechanisms of aflatoxin carcinogenesis. Annu Rev Pharmacol Toxicol (1994) 1.80
Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest (2013) 1.77
The chemistry and biology of aflatoxin B(1): from mutational spectrometry to carcinogenesis. Carcinogenesis (2001) 1.50
DNA damage induced by temozolomide signals to both ATM and ATR: role of the mismatch repair system. Mol Pharmacol (2004) 1.40
Elevated aflatoxin exposure and increased risk of hepatocellular carcinoma. Hepatology (1996) 1.36
Mechanisms of carcinogenicity/chemotherapy by O6-methylguanine. Mutagenesis (2002) 1.34
Whole-genome reconstruction and mutational signatures in gastric cancer. Genome Biol (2012) 1.33
TP53 Mutational signature for aristolochic acid: an environmental carcinogen. Int J Cancer (2011) 1.30
Mutational properties of the primary aflatoxin B1-DNA adduct. Proc Natl Acad Sci U S A (1996) 1.29
The epidemiology, diagnosis, and management of aristolochic acid nephropathy: a narrative review. Ann Intern Med (2013) 1.23
A model of interaction: aflatoxins and hepatitis viruses in liver cancer aetiology and prevention. Cancer Lett (2009) 1.15
The aflatoxin-induced TP53 mutation at codon 249 (R249S): biomarker of exposure, early detection and target for therapy. Cancer Lett (2009) 1.09
Mutations of the p53 tumor suppressor gene and ras oncogenes in aflatoxin hepatocarcinogenesis. Mutat Res (1996) 1.08
Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid. Mutat Res (2013) 1.02
Aflatoxin B1-induced DNA damage and its repair. Cancer Lett (2006) 1.00
Genomic impact of cigarette smoke, with application to three smoking-related diseases. Crit Rev Toxicol (2012) 1.00
Temozolomide in the treatment of solid tumours: current results and rationale for dosing/scheduling. Crit Rev Oncol Hematol (2005) 0.97
Genotoxicity of benzene and its metabolites. Mutat Res (2004) 0.94
Local uses of Aristolochia species and content of nephrotoxic aristolochic acid 1 and 2--a global assessment based on bibliographic sources. J Ethnopharmacol (2009) 0.94
Updating IARC's carcinogenicity assessment of benzene. Am J Ind Med (2010) 0.89
A high-throughput next-generation sequencing-based method for detecting the mutational fingerprint of carcinogens. Nucleic Acids Res (2012) 0.89
A review of molecular mechanisms in the development of hepatocellular carcinoma by aflatoxin and hepatitis B and C viruses. J Environ Pathol Toxicol Oncol (2013) 0.87
Characterization of the aqueous extract of the root of Aristolochia indica: evaluation of its traditional use as an antidote for snake bites. J Ethnopharmacol (2012) 0.86
Occupation and risk of lymphoid and myeloid leukaemia in the European Prospective Investigation into Cancer and Nutrition (EPIC). Occup Environ Med (2013) 0.86
Benzo[a]pyrene and its analogues: structural studies of molecular strain. Carcinogenesis (1997) 0.83
Synergistic hepatocarcinogenic effect of hepadnaviral infection and dietary aflatoxin B1 in woodchucks. Cancer Res (1995) 0.82
Human papilloma virus molecular profile and mechanisms of cancerogenesis: a review. Eur J Gynaecol Oncol (2009) 0.81
Occupational benzene exposure and the risk of chronic myeloid leukemia: a meta-analysis of cohort studies incorporating study quality dimensions. Am J Ind Med (2012) 0.79
Comparison of the repair of DNA damage induced by the benzene metabolites hydroquinone and p-benzoquinone: a role for hydroquinone in benzene genotoxicity. Carcinogenesis (2004) 0.78
Comparison of mutagenic potentials and mutation spectra of benzene metabolites using supF shuttle vectors in human cells. Mutagenesis (2004) 0.78
Carcinogenesis and infection with Helicobacter pylori. Rom J Intern Med (2010) 0.76